Published in Cancer Weekly, November 2nd, 2004
"Fatty acid synthase (FAS) activity is a potential therapeutic target to treat cancer and obesity... . Pharmacological FAS inhibitors cerulenin and C75 were found to suppress p185(HER2) oncoprotein expression and tyrosine-kinase activity in breast and ovarian HER2 overexpressors," said J.A. Menendez, Evanston NW Healthcare, Indiana, and colleagues.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.